Alnylam Pharmaceuticals Inc. (ALNY): Price and Financial Metrics

Alnylam Pharmaceuticals Inc. (ALNY): $145.16

0.16 (-0.11%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add ALNY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#34 of 362

in industry

ALNY Price/Volume Stats

Current price $145.16 52-week high $218.88
Prev. close $145.32 52-week low $143.52
Day low $144.23 Volume 398,900
Day high $146.47 Avg. volume 798,465
50-day MA $152.90 Dividend yield N/A
200-day MA $174.23 Market Cap 18.28B

ALNY Stock Price Chart Interactive Chart >


Alnylam Pharmaceuticals Inc. (ALNY) Company Bio


Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. (Source:Wikipedia)


ALNY Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream


Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug

The clearance of Wainua for transthyretin amyloidosis opens up a new front in a long-running commercial battle between Ionis and Alnylam.

Yahoo | December 22, 2023

13 Most Promising Healthcare Stocks According to Analysts

In this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […]

Yahoo | December 19, 2023

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

CAMBRIDGE, Mass., December 13, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2024, including continued commercial execution of four RNAi therapeutic products and the advancement of early-, mid-, and late-stage investigational programs.

Yahoo | December 13, 2023

Alnylam to Webcast Virtual R&D Day

CAMBRIDGE, Mass., December 06, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event.

Yahoo | December 6, 2023

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023

CAMBRIDGE, Mass., November 30, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the "Largest Employer" category. This marks the third year in a row that Alnylam has taken the top spot in the Largest Employer category (> 1,000 employees).

Yahoo | November 30, 2023

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo -1.91%
3-mo -21.12%
6-mo -10.28%
1-year -28.44%
3-year 6.71%
5-year 76.87%
YTD -24.16%
2023 -19.46%
2022 40.14%
2021 30.48%
2020 12.85%
2019 57.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!